![](https://ml.globenewswire.com/media/4086a689-17b2-4681-af7c-f5a84afe3011/medium/neo100-01-phase-i-survival-rate.jpg)
NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent ...
FDA approval reflects positive results from Phase I and preliminary results from Phase IIa study currently underway that demonstrate increased survivability rates in patients with the IDH1 marker. Trial expands from patients afflicted with Recurrent Grade …